India drugs inquiry could prompt new U.S. scrutiny

An Indian parliamentary panel on Wednesday said officials of India’s drug regulator had been colluding with pharmaceutical companies to speed up approval procedures, allowing some drugs that are not permitted in other countries to go on sale. The 78-page report by Indian lawmakers named several major international drug companies including Eli Lilly and Co. and Novartis.

This story is exclusively for members of the

JUST ANTI-CORRUPTION COMMUNITY

Log-in

E-mail Address or UserName: *

Password: *

Lost your password?

Click here to subscribe to
Just Anti-Corruption

For information about pricing, click here.

ERNST & YOUNG LLP's BRIAN LOUGHMAN ON TRENDS IN GLOBAL FORENSIC ACCOUNTING: Loughman, the Americas leader of Fraud Investigation & Dispute Services, discusses how increased government enforcement, awareness of corruption risk and an emphasis on proactive compliance assessments by corporations is driving double-digit growth in the New York-based practice he leads.

FCPA TRIAL FIRM OF THE YEAR: Finalists are announced in Main Justice's 2013 Best FCPA Lawyer Client Service Awards category, Trial Firm of the Year. The diamond award went to Eric Bruce and Matt Menchel of Kobre & Kim LLP for their defense of two FCPA sting trial defendants.

Mary B. Jacoby

Mary Jacoby is the founder of Main Justice and Editor-in-Chief of Just Anti-Corruption.

Ernst & Young's FIDS Practices

Dealing with complex issues of fraud, regulatory compliance and business disputes can detract from efforts to achi...more

USDOJ: CRIMINAL DIVISION NEWS

GOVERNMENT AND NGO SITES